期刊
CANCER JOURNAL
卷 17, 期 5, 页码 351-358出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/PPO.0b013e3182325d4d
关键词
Calreticulin; HMGB1; NLRP3; TLR4; ATP; dendritic cells
类别
资金
- Association pour la Recherche sur le Cancer (ARC)
- Ligue Nationale contre le Cancer (LIGUE)
- INSERM
- European Commission
- Ligue Nationale contre le Cancer
- Agence Nationale pour la Recherche
- AXA Chair for Longevity Research
- Fondation Bettencourt-Schueller
- Fondation pour la Recherche Medicale
- Institut National du Cancer
- Canceropole Ile-de-France
- Ligue contre le Cancer
- EU
- INCa
- Fondation de France
For a long time, anticancer therapies were believed to work (and hence convey a therapeutic benefit) either by killing cancer cells or by inducing a permanent arrest in their cell cycle (senescence). In both scenarios, the efficacy of anticancer regimens was thought to depend on cancer cell-intrinsic features only. More recently, the importance of the tumor microenvironment (including stromal and immune cells) has been recognized, along with the development of therapies that function by modulating tumor cell-extrinsic pathways. In particular, it has been shown that some chemotherapeutic and radiotherapeutic regimens trigger cancer cell death while stimulating an active immune response against the tumor. Such an immunogenic cell death relies on the coordinated emission of specific signals from dying cancer cells and their perception by the host immune system. The resulting tumor-specific immune response is critical for the eradication of tumor cells that may survive therapy. In this review, we discuss the molecular mechanisms that underlie the vaccine-like effects of some chemotherapeutic and radiotherapeutic regimens, with particular attention to the signaling pathways and genetic elements that constitute the prerequisites for immunogenic anticancer therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据